Peter R. Galle, MD, PhD - Moving Forward with the Management of Unresectable Hepatocellular Carcinoma: Evaluating the Impact of Emerging First-line Dual Immunotherapy Combination Regimens

Please visit answersincme.com/SSF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the rationale for evolving first-line treatment approaches in patients with unresectable hepatocellular carcinoma (HCC); Describe the clinical profiles of emerging first-line dual immunotherapy combination regimens for the treatment of unresectable HCC; and Outline strategies to optimally manage toxicities associated with first-line dual immunotherapy combination regimens for the treatment of unresectable HCC.

There are no comments yet.

Please log in to write the first comment.